Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab

View through CrossRef
<p>Figure S1A. Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B. Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C. Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D. Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E. Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F. Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A. Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B. Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C. Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>
Title: supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Description:
<p>Figure S1A.
Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B.
Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C.
Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D.
Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E.
Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F.
Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A.
Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B.
Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C.
Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>.

Related Results

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Abstract Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or whole RNA sequencing. Supplementary figure 2: Phylogeny and WGD events in ...
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or whole RNA sequencing. Supplementary figure 2: Phylogeny and WGD events in ...

Back to Top